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Abstract
Background: Untreated heterozygous familial hypercholesterolaemia (FH) causes high low-density lipoprotein
cholesterol (LDL-C) levels and increased cardiovascular disease (CVD) risk. Despite pharmacological treatment, many
treated individuals remain at higher CVD risk than non-affected individuals. This may be due to LDL-C targets not
being met and presence of other CVD risk factors. Adhering to dietary and physical activity (PA) recommendations
developed for individuals with FH may further reduce CVD risk. However, there is insufficient research to support
the efficacy of adhering to these guidelines on LDL-C and other CVD risk factors. The need for studies to investigate
the effectiveness of nutrition and PA interventions in the FH population has been widely recognised and
recommended. This paper describes the protocol of a pilot, randomised controlled trial designed to evaluate the
feasibility and acceptability of a specifically developed nutrition and PA intervention aimed at improving the dietary
intakes and PA levels of families with FH.
Methods: A two-arm randomised waitlist-controlled pilot trial will be conducted across three National Health
Service (NHS) sites in England, UK. Twenty-four young people with FH, aged 10–18 years, and their affected parent,
will be recruited and randomly assigned to the intervention or waitlist and usual care control. The primary aim is to
provide evidence for the feasibility and acceptability of delivering the intervention, explored quantitatively (rates of
recruitment, retention and outcome measure completeness) and qualitatively (qualitative interviews). The secondary
aim is to provide evidence for the potential efficacy of the intervention on dietary intake, PA, sedentary time, body
composition, CVD risk factors and quality of life determined at baseline and endpoint assessments. The intervention
will involve an hour-long consultation with a dietitian at baseline and four follow-up contacts across the 12-week
intervention. It has been specifically developed for use with individuals with FH and incorporates behavioural
change techniques to target identified enablers and barriers to adherence in this population.
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Discussion: This trial will estimate the feasibility and acceptability of the nutrition and PA intervention delivered to
young people and parents with FH. If appropriate, this study can be used to inform the design of an adequately
powered definitive trial.
Trial registration: ISRCTN, ISRCTN24880714. Registered 07/06/2018, http://www.isrctn.com/ISRCTN24880714.
Keywords: Familial hypercholesterolaemia, Diet, Physical activity, Cardiovascular disease, Intervention, Dietetics,
Paediatrics, Primary prevention, Qualitative, Feasibility
Background
Heterozygous familial hypercholesterolaemia (FH) is
an autosomal dominant hereditary disorder, charac-
terised by markedly elevated levels of low-density
lipoprotein cholesterol (LDL-C) from birth [1]. The
lifelong exposure to elevated LDL-C levels confers a
substantially increased risk of premature cardiovascu-
lar disease (CVD) and associated mortality [2] to the
1 in 250 people affected worldwide [3]. While the
introduction of pharmacological treatment has dra-
matically reduced the incidence of CVD in individuals
with FH, they remain at increased risk [4–7]. The re-
sidual CVD risk may be attributed to the large num-
ber of adults and young people that do not reach
LDL-C treatment targets, even on maximally tolerated
doses [8, 9]. Additionally, the presence of other risk
factors such as hypertension, obesity and type II dia-
betes have been shown to be independently associated
with their CVD risk [6, 10–14]. Efforts are currently
focussed on improving the low overall detection of
this disorder, which is estimated to be identifying
only 1–15% of those at risk worldwide [15]. It is
therefore crucial to optimise the treatment provided
to this rapidly increasing vulnerable patient popula-
tion group.
Lifestyle advice is considered an important adjuvant
to pharmacological treatment for individuals with FH.
All individuals are recommended to receive individua-
lised advice about diet, physical activity and the
maintenance of a healthy weight from a healthcare
professional (HCP) with specific expertise [16–18].
Dietary and physical activity recommendations are
based on the same principles as advised for the general
population, with additional emphasis to reduce intakes
of foods high in fat, saturated fat and cholesterol and
to consume foods with LDL-C-lowering effects such
as plant phytosterols/phytostanol s[16–18].. Despite
these recommendations, comprehensive systematic re-
views have concluded that there is insufficient data to
make any conclusions about the effectiveness of any
dietary or physical activity intervention upon CVD risk
or surrogate outcomes in adults or young people with
FH [19, 20]. Extrapolating the results of such interven-
tions carried out in other patient populations is
inappropriate as this does not allow for consideration of
the unique physiological and psychological factors present
in individuals with FH. Randomised controlled trials
(RCTs) to investigate the effectiveness of dietary and phys-
ical activity interventions within FH cohorts have been
recommended to address this research gap [18–21].
An understanding of how and why individuals with
FH display certain behaviours and an awareness of the
factors influencing their decisions to adhere to treatment
should be considered in the development of an interven-
tion. Adherence to lifestyle recommendations in affected
individuals is sub-optimal whereby less than 50% of adults
reported following the recommended lifestyle advice [22].
Additionally, overweight and obesity has been reported in
cohorts of adults and young people with FH, suggesting
that the advice is not being followed by all [9, 14, 23].
Given the chronic nature of FH, it is essential that an
intervention enables individuals to make lifelong behav-
ioural changes, rather than for the short duration of a clin-
ical trial. As the greatest reduction in CVD risk is
achieved when treatment is started at a young age [4, 24],
young people stand to gain the most for receiving a life-
style intervention. Given the increasing diagnostic rates
and high prevalence of FH, any intervention to be evalu-
ated should also be pragmatic and feasible to provide
within the constraints of current healthcare services.
In the current research, we propose to develop and
evaluate a family-based nutritional and physical activity
intervention to enable young people with FH, and their
affected parent, to achieve dietary and physical activity
recommendations thus reducing their CVD risk. As
there is currently insufficient evidence to support a large,
full-scale RCT to evaluate such an intervention, a pilot
RCT is needed as advised in the British Medical Re-
search Council (MRC) framework for the development
and evaluation of complex interventions [25, 26].
Study aims and objectives
The primary aim of this study is to provide evidence for
the feasibility and acceptability of conducting a future
adequately powered, randomised controlled trial to
evaluate a specifically designed nutrition and physical ac-
tivity intervention in young people and their affected
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parent with FH. The primary objectives of the study are
to explore the following questions:
1. Will young people and their parent be willing to
participate in the proposed family-based
intervention?
2. Will families accept randomisation to the control or
intervention group, adhere to research methods in
their allocated group and complete the study?
3. Are the research methods that are used to capture
data fit for purpose?
4. Is there sufficient protocol fidelity in the
intervention group?
5. Upon completion of the study, was the overall
experience of the intervention and/or the study
research processes positive and potentially
reproducible in an adequately powered trial?
The secondary aim of this study is to estimate the po-
tential efficacy of the intervention on the dietary intake,
physical activity and sedentary time, body composition,
selected CVD risk factors and quality of life of young
people and their affected parent with FH.
Methods
This protocol is reported in accordance with SPIRIT
(Standard Protocol Items: Recommendations for Inter-
ventional Trials) guidance and a completed checklist is
available in Additional File 1.
Study design and setting
This pilot study is a two-arm, randomised waitlist-
controlled trial comparing a specifically developed nutri-
tion and physical activity intervention against usual-care
waitlist control amongst young people with FH. This
study aims to recruit family units, each comprised of a
young person-parent dyad. This is in recognition of the
autosomal dominant presentation of FH which means all
affected young people will have one affected parent. This
will also facilitate the proposed family-based delivery of
the intervention. This study will be conducted across
three National Health Service (NHS) Foundation Trust
sites in England, UK: University Hospitals Bristol, Royal
United Hospitals Bath and St. George’s University Hos-
pitals London (Fig. 1).
Study population
In this family-based intervention, young person(s) aged
10–18 years and their affected parent with FH will be in-
vited to participate. A family unit will be comprised of at
least one adult and one young person with FH, but there
may also be family units in which additional young fam-
ily members with FH take part.
Eligibility criteria
Individuals aged 10–18 years with a genetically con-
firmed clinical diagnosis of heterozygous FH who receive
their care from the paediatric or adult lipid clinics at the
three NHS Foundation Trust sites will be invited to join
the study. Their parent (≥ 18 years), with a genetically
confirmed clinical diagnosis of heterozygous FH, will
also be invited to join the study.
Pregnant female patients, or those planning pregnancy,
and individuals who are unable to give informed consent
or assent for those aged 10–15 years are not eligible for
participation. Patients with a diagnosis of homozygous
FH and patients not established on their current treat-
ment regimen for at least 1 month prior to recruitment
to the study are not eligible for participation.
If a young person with FH wishes to join the study
but their affected parent is deceased or does not
want, or is not eligible to participate, then the young
person will still be able to participate. In this in-
stance, a non-affected parent or main carer of the
young person will be invited to take part to facilitate
the family-based aspect of the study if they wish.
However, blood samples will not be collected from
these non-affected participants. In instances where the
non-affected parent or main carer also does not wish
to take part, the young person with FH will still be
able to participate on their own.
Recruitment
Identification
All young people receiving care from paediatric or adult
lipid clinic services at participating sites will be screened
for eligibility. The eligibility of their affected parent will
then be considered. This will be carried out by a mem-
ber of the hospital care team and will be repeated every
3 months during the recruitment phrase. This will be
conducted at both paediatric and adult clinics because
young adults often transition to adult services before the
age of 18 years.
Invitation to participate
A study invitation letter and an age-appropriate partici-
pant information sheet (PIS) will be sent to the families
of young people who are identified and deemed to meet
the inclusion criteria from review of medical records. A
PIS will also be included for the parent of the identified
young person. Contact details of the research team are
provided in this PIS and families interested in participa-
tion are asked to make contact. The study will also be
described, and a PIS provided, to young people and their
parent(s) attending either paediatric or adult lipid clinics.
For families expressing an interest in participation, a
meeting or phone call will be arranged with a member
of the research team.
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Sample size
This is an exploratory feasibility study and therefore no
power calculation has been used to determine sample
size because it is not designed or powered to address the
effectiveness of the intervention being evaluated [25, 27,
28]. Sample sizes of between 24 and 50 have been rec-
ommended for feasibility studies wishing to provide a
standard deviation estimation to inform the sample size
calculation of a larger RCT [27, 29, 30]. The target sam-
ple size of 24 family units in this study has been based
upon this recommendation in addition to knowledge of
the current local FH population.
Randomisation and blinding
Randomisation, stratified by study site, will allocate family
units to either usual care and waitlist (control) or to the
Fig. 1 Study flow diagram
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nutrition and physical activity intervention (intervention)
on a 1:1 basis. To facilitate recruitment and retention,
family units allocated to the control arm will be placed on
a waitlist to receive the intervention at the end of the 12-
week study period. Randomisation will be carried out by
an independent person using prepared, password-
protected randomised lists, following obtainment of in-
formed consent to participate. Family units will be notified
of their assigned group at research visit two, after baseline
data collection. Due to the nature of the intervention, de-
livery and study design, it is not possible to blind partici-
pants, clinical staff or research staff to the randomisation
results. Upon completion of the study, participants in the
control group will be asked if they had any communication
with other young person-parent dyads in the study. This
will assess potential intervention contamination bias which
will be taken into consideration in the analysis. The antici-
pated likelihood of this occurring is low due to the infre-
quency of outpatient appointments (usually once a year)
that families attend.
Intervention
Family units randomised to the intervention group will
receive an individualised, family-based nutrition and
physical activity intervention developed specifically for
this study. It will be delivered to the family at research
visit two by a dietitian and will last approximately 1 h.
This will be followed up with four phone calls or email
correspondence (according to participant preference) at
weeks 2, 4, 8, and 11 of the intervention. Age-specific
intervention booklets (10–13 years and ≥ 14 years) have
been developed for use in the intervention. These will be
provided to the participants at research contact two to
enable participants to refer to the intervention informa-
tion during the 12-week intervention and follow-up ses-
sions. If a young person is participating without a
parent, the intervention content and delivery will be
changed to facilitate this.
Intervention content and delivery
The development and content of the intervention has
been described in full elsewhere [31], but will be de-
scribed briefly. Intervention aims to enable participants
to achieve the dietary intakes and physical activity levels
currently recommended for people with FH. A literature
review of the available guidelines for the management of
FH was conducted to determine the following targets for
daily dietary intakes and weekly physical activity levels:
1. Total fat intake ≤ 30% of total energy intake (TEI)
2. Saturated fat intake of ≤v10% TEI achieved via
replacement of saturated fats with
monounsaturated and polyunsaturated fats
3. Dietary cholesterol intake ≤ 300 mg
4. Consumption of ≥ 5 portions of fruit and vegetables
5. Age appropriate fibre intake: 10-year-olds = 20 g/
day; 11–16 year-olds = 25 g/day and 30 g/day for ≥
17 years
6. 2 g of plant stanol/sterols
7. Reduce time spent engaged in sedentary behaviours
8. Age appropriate physical activity levels:
 Adults: ≥ 150 min a week of moderate intensity
physical activity or ≥ 75 min of vigorous intensity
physical activity, or a mixture of the two. Additional
activity focussing on improving muscle strength
should be undertaken twice a week.
 Young people: ≥ 60 min of moderate-to-vigorous
physical activity (MVPA) each day, with three of these
sessions each week being of vigorous intensity and in-
cluding activities that strengthen muscle and bone.
Evidence suggests that behaviour change interventions
based on theory are more successful than those devel-
oped without a theoretical base [32]. As there are many
theoretical models, but no consensus on which one is
superior, the theoretical domains framework (TDF) was
used in the development of this intervention [33]. The
TDF brings together 33 psychological theories that are
relevant to behaviour change and sorts them into 84
constructs (the component parts of theories) which have
been organised into 14 domains (broader areas in which
a theory may be applied, e.g. motivation). This TDF can
be used as a framework to identify barriers and facilita-
tors to achieving behaviour change and has been vali-
dated for use in developing theoretically informed
interventions [33]. To develop an understanding of be-
havioural factors influencing adherence to treatment in
people with FH a qualitative evidence synthesis was con-
ducted by our team. This synthesis identified enablers
and barriers to treatment adherence in young people
and adults with FH [34] which were then mapped onto
the TDF domains. Appropriate behaviour change tech-
niques (BCTs) to target these domains were selected
using a 93-item BCT taxonomy [35]. The utility of these
BCTs in this intervention were considered in relation to
the APPEASE criteria: affordability, practicality, effect-
iveness, cost-effectiveness, acceptability, side-effects/
safety and equity [36]. A total of 26 BCTs have been in-
corporated into the intervention. The intervention will
be delivered to all participants by one of two dietitians.
Control group
Family units assigned to the control group will be in-
formed that they are on a waitlist to receive the inter-
vention at the end of the 12-week study period and
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receive usual care. At the three NHS sites involved, usual
care is comprised of an annual appointment with a lipid
clinic doctor and continuation on their pharmacological
treatment, if applicable. Young people are not offered
the opportunity to receive dietetic advice when attending
paediatric outpatient visits and young people and adults
are given an option to receive advice at their first adult
clinic outpatient visit. Therefore, it is unlikely that any
participant on the waitlist control will receive dietetic ad-
vice during the 12-week intervention period; however, this
will be monitored. These family units will not be con-
tacted during the 12-week intervention period, except be-
fore week 12 to arrange the endpoint dietary and physical
activity assessments ahead of research visit three.
Primary aim outcomes
Feasibility and acceptability outcomes (study objectives 1, 2
and 3)
The feasibility and acceptability will be estimated
through recruitment, randomisation and retention rates,
attendance at study visits, completion rates of question-
naires, completeness of dietary intake and physical activ-
ity data and rates of successful collection of clinical
measurements (blood samples, anthropometric measure-
ments and blood pressure).
Intervention fidelity and evaluation outcomes (study
objective 4)
To explore if the intervention is delivered as intended,
the dietitians will complete checklists and record de-
tailed reflections for each intervention and follow-up
session. Details of the goals set, and self-reported attain-
ment by participants during follow-up sessions, will be
recorded in case report forms (CRFs). Intervention in-
tensity will be estimated through recording the number
and duration of any face to face, email and telephone
contact with participants. The potential mechanisms of
impact will be explored through descriptive analysis of
this data, along with qualitative data collection from par-
ticipants in the intervention group. Exploration of these
outcomes will enable the intervention to be refined be-
fore utilisation in future studies.
Qualitative outcomes (study objective 5)
The acceptability of the intervention and the research
methods used will be explored through additional data
regarding the acceptability of the intervention and re-
search methodology collected from semi-structured
qualitative interviews. The sub-sample selected for inter-
view will comprise of up to 30 participants based on
sample sizes in previous similar studies [37–42]. It will
also include participants who did not want to take part
in the full research study but consented to the qualita-
tive component of the study (Fig. 1). A purposive
sampling approach, using a maximum variation method,
will be taken to select participants for the sub-sample
according to individual characteristics, opinions and ex-
periences relevant to this study [43, 44]. Separate topic
guides have been developed for adults and young people
to provide some structure to the interviews.
The qualitative data will also be used to help understand
how and why the intervention was effective or ineffective
and if the intervention will be successful in a wider con-
text [26, 45, 46]. It will also be used to help improve the
design and conduct of any future trials [26, 47].
Secondary aim outcomes
The potential efficacy of the developed intervention
upon dietary intakes, physical activity and sedentary
time, body composition, CVD risk factors and quality of
life will be estimated. This will be done through meas-
urement of changes in a range of clinical and behav-
ioural outcomes before and after the intervention period.
Results will also be used to estimate the variability of
each outcome measure and to identify the suitability of
the outcome tools/measures chosen to detect any
changes. When possible, standard deviation of the out-
come measure will be calculated to inform the sample
size calculation of a future large-scale RCT.
Behavioural outcomes (dietary intake, physical activity,
sedentary time) will be assessed in the week immediately
preceding research visits two and three (Fig. 1). An-
thropometric, clinical and biochemical outcomes, and
quality of life measures will be collected at baseline and
endpoint assessments conducted at research visits two
and three (Fig. 1). Further details of each outcome are
provided below and in Table 1.
Dietary intake
Participants will record their dietary intake over four
non-consecutive days (including one weekend day) using
INTAKE24, an online 24-h recall tool. INTAKE24 is a
validated, self-completed computerised dietary recall sys-
tem based on multiple-pass 24-h recall developed specif-
ically for young people. It is a secure tool, accessed by
individually issued log-on details. It has been found to pro-
duce mean daily energy and nutrient intakes comparable
with interviewer-led 24-h recalls in young people aged 11–
24 years, at a significantly lower cost [48]. This method of-
fers several benefits over traditional paper-based methods,
such as pre-programmed completeness checks, prompts
and food photographs to improve data capture. The auto-
mated coding system ensures consistency of coding and
removes the risk of data entry errors. Furthermore, newer
technology-based methods of dietary assessment have been
demonstrated to be preferred by young people and adults
compared to traditional methods [49–52]. Participants will
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Table 1 Outcome measures, data collection methods and time points
Study aim Objectives being explored Outcome measures Data collection method/tool Time point collected (weeks)
− 1 − 1 to 0 0 11–12 12
Primary: Feasibility
and acceptability
1. Will young people and
their parent be willing to
participate in the proposed
family-based intervention?
2. Will families accept
randomisation to the
control or intervention
group, adhere to
research methods in
their allocated group
and complete the study?
3. Are the research
methods that are used
to capture data fit for
purpose?
Recruitment, retention,
randomisation and
adherence to protocol
rates
Screening, recruitment
and randomisation logs,
monitoring of study visit
attendance, successful
collection of clinical
outcome measures and
withdraw/loss to follow
up records.
Continuous during
data collection period
4. Is there sufficient
protocol fidelity in the
intervention group?
Intervention intensity
and adherence to
intervention protocol
and delivery
Self-completed checklists
and recording of the
number & duration of
contact with participants
5. Upon completion of
the study, was the overall
experience of the
intervention and/or the
study research processes
positive and potentially
reproducible in an
adequately powered trial?
Self-reported experiences
and beliefs of participants
regarding the study
methodology &/or
intervention
Semi-structured qualitative
interviews
x
Secondary: Potential
efficacy
No specific objectives
stated for this secondary
study aim
Patient characteristics:
medication, education
levels, smoking status
and FH genetic variant
CRF developed for study x x x
QoL score (HRQoL and
component physical,
emotional, social and
school functioning scores
for young people and
single index value and
VAS rating for adults)
Age appropriate PedsQL™
QoL inventory or EUROQOL
5D-3L health questionnaire
x x
Mean fat, saturated fat,
monounsaturated fat,
polyunsaturated fat, fibre,
plant sterol/stanols,
cholesterol and fruit and
vegetable intake per day
(grams and % of daily
energy intake)
INTAKE24 online dietary recall
system completed for 4 days
x x
MVPA (min/day) ActiGraph GT3X+
accelerometer worn for
7 days
x x
Time spent sitting/lying,
standing and walking
(min/day)
activPAL3 accelerometer
worn for 7 days
x x
Self-reported physical
activity levels (MET minutes
per week and categorised
into high, medium or low
level groups for adults and
assigned score between 1
and 5 for young people, in
which 1 indicates low levels
and 5 high levels, of PA)
Age appropriate IPAQ,
PAQ-A or PAQ-C
questionnaire
x x
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be asked about their consumption of supplements and
plant stanol/sterol fortified foods at research visits 2 and 3.
The data will be analysed to produce mean daily in-
takes of fat, saturated fat, monosaturated fat, polyunsat-
urated fat, cholesterol, plant stanols/sterols, fibre and
fruits and vegetables.
Physical activity levels
Free-living MVPA will be measured using an ActiGraph
GT3X+ accelerometer (ActiGraph, Pensacola, USA),
worn by participants on an elasticated belt on the waist
above the midline of the right thigh for seven consecu-
tive days, except for water-based activities. This is a tri-
axial device that detects the frequency and amplitude of
acceleration in three axes. Participants will also be asked
to complete a physical activity log book, to capture wak-
ing/sleeping times and any activities which required the
monitor to be taken off. When processing the data, age-
and sex-specific cut points will be applied to define seden-
tary time, light, moderate and vigorous physical activity
during waking hours. Total daily time spent in MVPA will
be obtained by totalling the duration of all moderate and
vigorous physical activity bouts for each day. This value
will then be averaged over the number of valid days to de-
termine mean time spent in MVPA per day.
Self-report measures of physical activity have been
found to overestimate MVPA in young people [53] and
adults [54]. However, self-report and objective measures
have not been compared within populations of individ-
uals with FH. Self-report measures are more practical
and less burdensome for study participants and may be
a more appropriate outcome measure to use in a future
larger scale trial. Thus, each participant will also
complete age appropriate physical activity self-report
questionnaires. For adults, the International Physical Ac-
tivity Questionnaire (IPAQ) will be used which is a vali-
dated self-report tool for measuring physical activity in
adults aged 18–64 years old [55]. The Physical Activity
Questionnaire for Older Children (PAQ-C) [56] and Ad-
olescents (PAQ-A) [57] will be used with participants
aged 10–14 years and 15–18 years old respectively, as
recommended by a comprehensive systematic review
and expert panel consensus [58]. These questionnaires
will be scored to assign individuals into one of five cat-
egories which indicate low to high levels of physical ac-
tivity. These will be compared to the objective MVPA
measurements.
Sedentary time
This will be measured using an activPAL3 accelerometer
(PAL Technologies Ltd., Glasgow, UK) worn on the
front of the thigh. The activPAL3 will be made water-
proof using a nitrile sleeve and a waterproof hypoaller-
genic medical dressing will be used to attach it to the
leg, enabling participants to wear it continuously for 24
h/day over 7 days. It contains a tri-axial accelerometer
Table 1 Outcome measures, data collection methods and time points (Continued)
Study aim Objectives being explored Outcome measures Data collection method/tool Time point collected (weeks)
− 1 − 1 to 0 0 11–12 12
Anthropometric measurements:
height (cm), weight (kg), BMI
(kg/m2), body composition
including body fat (%) and fat
free mass (%)
Tanita body composition
analyser and stadiometer
x x
Systolic and diastolic
blood pressure (mmHg)
Mean of two measures by a
sphygmomanometer (three
measures if 1st and 2nd differ
by more than 10mmHg)
x x
Serum concentrations
(mmol/l) and component
lipid breakdown (mmol/l
and %) of different classes
(very large, large, medium
and small) of VLDL, LDL,
HDL particles; mean
diameter of VLDL, LDL &
HDL particles (nm); serum
concentration of total
cholesterol, LDL, HDL,
HDL2, HDL3, remnant
cholesterol, triglycerides
(mmol/l) and
Apolipoproteins (g/l).
Metabolomic analysis of
serum samples obtained
from processing of 25ml
whole blood samples
x x
CRF case report form, QoL quality of life, VAS visual analogue scale, MVPA moderate-to-vigorous physical activity, IPAQ International Physical Activity Questionnaire,
PAQ-A the Physical Activity Questionnaire for Adolescents, PAQ-C the Physical Activity Questionnaire for older Children, BMI body mass index, VLDL very large
density lipoprotein, LDL low-density lipoprotein, HDL high-density lipoprotein
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which responds to signals related to gravitational forces
and provides information on thigh inclination [59]. This
allows for precise differentiation between postures in
prolonged free-living activities [60] and represents a
valid measure of time spent sitting/lying, standing and
walking in adults [61, 62] and young people [63–65].
Total daily time spent sitting/lying, standing and walking
will be obtained for each day and will be averaged over
the number of valid days across all waking hours.
Participant characteristics
Information about smoking status, education, medica-
tion and FH genetic variation will be obtained from par-
ticipants and used to characterise the intervention and
control groups.
Anthropometric and other clinical measurements
Height and weight will be measured to determine body
mass index (BMI). Resting systolic and diastolic blood
pressure will be estimated by averaging two separate
measurements using a sphygmomanometer. Blood pres-
sure and BMI have been chosen as outcome measures
due to research finding these to be independently associ-
ated with CVD risk in adults with FH [66]. There has
been no similar research carried out in young people
with FH; however, BMI and blood pressure have been
reported to independently influence future CVD risk in
young adults without FH [67].
Body composition will be measured using bioelectrical
impedance (Tanita™ MC-780MA) with attention paid
specifically to fat and fat-free mass. While no research to
date has investigated the role of these outcomes mea-
sures upon CVD risk in individuals with FH, they have
been found to influence the serum blood lipid levels of
young people without FH [68]. Therefore, these mea-
sures will help to characterise the participants in the
control and intervention groups and allow for interpret-
ation of any changes in serum lipid levels observed in
participants before and after the intervention period.
Furthermore, changes in these outcomes have been
found to moderate the influence of physical activity in-
terventions upon blood lipid measures in adults without
FH [69, 70] highlighting the need for future research to
control for such measures.
Quality of life
The need for further research to explore the potential
detrimental impacts that individuals with FH may ex-
perience as a result of making changes to their diet and
physical activity levels was highlighted in a Cochrane
systematic review [20]. Therefore, the Quality of life
(QoL) of all participants will be measured.
Young person participants will be asked to complete
an age-appropriate Pediatric Quality of Life Inventory ™
(PedsQL™) Version 4.0. The PedsQL 4.0 Generic Core
Scales will be used which have been validated for meas-
uring the health-related quality of life (HRQoL) of young
people aged 2 to 18 years with chronic health conditions
[71]. This multidimensional self-report scale consists of
23 items, covering four domains of HRQoL: physical,
emotional, social and school. The completed inventories
will be scored using the recommended scoring system
[72] to produce a score for HRQoL and a breakdown of
the component physical, emotional, social and school
functioning scores.
Adult participants will be asked to complete an Euro-
Qol Group EQ-5D-3L health questionnaire as recom-
mended by NICE [73] and validated for use in European
adults [74]. Participants will be asked to rate their degree
of impairment in five health domains (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression)
using one of three responses (no problems, some prob-
lems and extreme problems). The recommended scoring
system will be used [75] which produces a five-digit
health state profile representative of five dimensions of
health. This will then be converted into a single index
value using a validated value set created for use in the
UK [76]. Participants will also be asked to rate their per-
ceived health by drawing a line to a point on a visual
analogue scale (VAS) between the endpoints of ‘best im-
aginable health state’ and ‘worst imaginable health state’.
The VAS data will be presented as a single value be-
tween 1 and 100.
Blood lipidomic markers
The primary aim in the treatment of FH is a reduction
in LDL-C concentrations [15]. However, it is recognised
that focussing on a single lipid marker does not ad-
equately reflect an individual’s overall risk of CVD or
the clinical effect of any pharmacological or lifestyle
treatment [17, 77]. Therefore, several lipidomic markers
have been selected as outcome measures (Table 1), al-
though these may change as the literature develops.
These have been chosen on the basis of their proposed
role in the prediction and development of CVD risk [17,
78] and/or sensitivity to change via dietary intakes and
physical activity as proposed in previous research [77,
79].
A maximum of 25 ml whole blood will be collected
from each participant which is within the safe limits ad-
vised by the World Health Organisation (WHO) for use
in child health research [80]. Blood samples will be col-
lected, stored and analysed in accordance with the Hu-
man Tissue Act 2004. Participants will be requested to
fast for a minimum of 6 h and to avoid strenuous phys-
ical activity for 12 h prior to sample collection.
Samples will be sent to the laboratory of the hospital
in which they were collected and will be processed
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according to the laboratory Standard Operating Proce-
dures and under the supervision of the laboratory team.
Once centrifuged, the sample will be split whereby some
of the sample will be analysed immediately to determine
the full lipid profile (LDL-C, HDL and total cholesterol)
in the hospital laboratory. The remainder of the sample
will be stored at − 80 °C as plasma in anonymously la-
belled microtubes in the hospital laboratory prior to trans-
port, contained in dry ice, to the University of Bristol
MRC Integrative Epidemiology Unit (IEU) Metabolomics
Facility. These samples will undergo batch metabolomic
analysis at the end of the data collection period to deter-
mine the levels of lipidomic markers.
Data collection
Quantitative data
All quantitative participant data will be collected on
anonymised purpose-designed CRFs or questionnaires.
These data will then be inputted into a study database
(Microsoft Access) by a member of the research team.
The database is password-protected and accessible only
by the chief and co-investigators.
Data from the activPAL and ActiGraph GT3X+ acceler-
ometers will be downloaded using custom software (PAL
Technologies Ltd., Glasgow, UK and ActiGraph, Pensa-
cola, USA, respectively). Raw data from the ActiGraph
GT3X+ accelerometer will be downloaded and analysed
using the manufacturer’s software (ActiLife software
v6.13.4; ActiGraph, Pansacola, FL, USA). The activPAL3
data will be downloaded using the manufacturer’s soft-
ware (PAL software v7.2.38; PAL Technologies Ltd., Glas-
gow, UK), and the raw data will be cleaned and processed
using a validated algorithm [81]. The participant’s physical
activity log-books will be used to aid identification of non-
wear periods and sleep time; these periods will be re-
moved from subsequent analysis. Data collected using the
INTAKE24 online tool will be downloaded and analysed
manually using Excel and statistical software.
Qualitative data
The audio-recorded qualitative data collected will be tran-
scribed verbatim by a member of the research team, or an
individual from a University of Bristol approved transcrip-
tion company, and stored using NVivo (NVivo10, QSR
International, 2012) data management software.
Withdrawal
Each participant will have the right to withdraw from
the study at any time. The study design aims to minim-
ise attrition by not overburdening participants but if
there is significant attrition (loss of more than 15 indi-
viduals) over the study period, additional individuals
with similar characteristics to those lost will be re-
cruited. Participants will be withdrawn from the study if
their hospital FH care team feel that their participation
is negatively affecting their clinical status. This includes
participants who become pregnant during the study as
they will be required by necessity to stop statin treat-
ment. A member of the hospital FH care team will in-
form the research dietitian of these cases. In all cases,
data collected up until the point of withdrawal will be
included in the analyses, unless the participant expresses
a wish for their data to be destroyed. If a reason for
withdrawal is given, this will be documented in the par-
ticipants CRF.
Analysis plan
Data collected from young people will be analysed separ-
ately from the data collected for adult parent participants.
Quantitative data
Recruitment, randomisation and retention rates, attend-
ance at study visits, completion rates of questionnaires,
completeness of dietary intake and physical activity data,
rates of successful collection of clinical measurements
and categorisation results of self-reported physical activ-
ity levels will be descriptively analysed. The other quan-
titative variables of interest (Table 1) are continuous.
Therefore, where possible, groups will be summarised by
means and standard deviations (S.D.) for (i) baseline, (ii)
end point assessment and (iii) for the changes over the
intervention period. This will be carried out for individ-
uals in the control and intervention groups.
Comparisons will be made between the endpoint as-
sessment means in the intervention and control groups
with or without adjustment for the baseline values and
stratification, as appropriate. 95% confidence intervals
(C.I.) will be reported for mean differences. Comparisons
may be made between the intervention and control
groups in respect of the mean changes from baseline if
this is found to improve precision [82].
Additionally, the dietary intake and physical activity
data at both baseline and endpoint assessment will be
compared to the target levels determined for the inter-
vention (outlined previously in ‘intervention content’)
and will be descriptively analysed for participants in the
control and intervention groups.
Qualitative data
Interview transcripts will be analysed using thematic
analysis [83, 84]. NVivo (NVivo10, QSR International,
2012) data management software will be used to manage
the transcript data. Thematic analysis involves coding
the interview transcripts, using an inductive approach.
This step will be carried out by two members of the re-
search team who will independently code data on a sub-
sample of the data set. The analysts will then discuss
their initial coding and endeavour to reach consensus
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about the codes assigned with the aim of developing a
definitive coding frame for the complete data set. Once all
transcripts have been coded inductively, the research team
members will work deductively to group codes into
themes associated with the research objectives of this
study. A descriptive, narrative approach will then be taken
to explore the findings in the context of the trial research
aims and their experiences of participation in the trial.
The findings will be presented using anonymised partici-
pant quotes to illustrate any identified themes.
Harms
There are no known risks to the participants in this study.
Any adverse event, regardless of relationship with the
study treatment, will be recorded and reported in accord-
ance with University Hospitals Bristol NHS Foundation
Trust and the University of Bristol (as sponsor) guidance.
Data monitoring
A Data and Safety Monitoring Board has not been formally
established, due to the low risk nature of the intervention.
All adverse events will be reported to the chief investigator
(FJK) and reviewed at monthly meetings with co-
investigators (JPHS and FEL) to determine whether the
study should be discontinued because of participant safety.
Auditing
The University of Bristol, as Sponsor of this study, has a
Service Level Agreement in place with University Hospi-
tals Bristol NHS Foundation Trust. As part of this agree-
ment, University Hospitals Bristol NHS Foundation Trust
will undertake monitoring of research projects where Uni-
versity of Bristol is fulfilling the responsibilities of Re-
search Sponsor. A minimum of 10% of projects will be
monitored. If this study is selected for audit, it would be
carried out independently to the study team and Sponsor.
Ethics and Dissemination
Research ethics approval
The study has been approved by the South West-
Cornwall & Plymouth Research Ethics Committee (REC)
(Reference: 18/SW/0121).
Protocol amendments
Any amendments to the protocol will be submitted to the
REC and Health Research Authority (HRA) for approval,
after permission is sought from the Sponsor. Only once
the amendment has been approved by the REC and HRA
and has received confirmation of continued capacity and
capability from NHS sites (or acknowledged in the case of
a minor amendment) will the amended protocol be imple-
mented. Deviations to the protocol outlined in the pub-
lished protocol will be highlighted in any subsequent
publication of the study findings.
Consent and assent
Written informed consent is required from all partici-
pants to participate in this study. For young persons
aged 10–15 years, this will be obtained from their parent
or guardian, with written informed assent also collected
from the young person. Informed consent will be sought
when patients attend the hospital for a routine clinic ap-
pointment or at the first research visit, prior to com-
mencing any data collection. A member of the research
team will be responsible for the consent process. There
will be an opportunity to discuss any remaining ques-
tions the participant may have with a member of the re-
search team prior to signing the consent or assent form.
A copy of the signed assent and/or consent form will be
filed in the participants’ medical records to ensure that
the hospital FH care teams are aware of their involve-
ment in the study. Eligible individuals who decline par-
ticipation in the study will be offered the option to
undertake the qualitative component of the research
study only. These individuals will receive a different PIS
outlining what is involved in this part of the study.
These individuals will be required to give informed con-
sent or assent prior to collection of any data.
All individuals will be advised that participation in the
study is voluntary and that they have the right to with-
draw at any time, without the need for explanation and
that their decision will not impact upon the care they
receive.
Confidentiality
All data will be anonymised, with participants identified
by a unique study number. Confidentiality will be en-
sured through the application of the University of Bristol
information security and data handling policies. These
are compliant with the Data Protection Act 2018 and
conform to the security standards of the NHS IG toolkit.
All participant information (i.e. names, addresses, dates
of birth etc.) will be stored separately from data collected
during the study (i.e. dietary intake) and participants will
be identified by a unique study number. Personal identi-
fiable paper records will be stored separately from anon-
ymised paper records and CRFs. All paper records will
be stored in secure storage facilities in University Hospi-
tals Bristol, Royal United Bath Hospital or St. George’s
Hospitals NHS trust sites. No personal data will leave
the sites until archiving at the end of the study. Elec-
tronic data will be stored securely using password-
protected databases on a University of Bristol computer
in the NIHR Biomedical Research Centre (Nutrition
Theme), Level 3 University Hospitals Bristol NHS Trust
Education and Research Centre. This is a secure site
within the Trust. The University of Bristol computer
hard drive is also encrypted. Only members of the study
team will have access to the dataset.
Kinnear et al. Pilot and Feasibility Studies            (2020) 6:42 Page 11 of 14
Dissemination policy
Summaries of preliminary findings will be produced for
study participants and the individual results for each
participant will be recorded in their medical records.
Manuscripts reporting the findings will be produced
for publication in relevant, peer-reviewed international
journals. As this is a feasibility study, the results will be
used to inform and develop a larger RCT, if appropriate,
which will be adequately powered to detect clinically sig-
nificant changes in outcome measures.
Patient and public involvement
Two events have taken place with patient and public
involvement:
1. Seven individuals, three young people and four adults,
with FH under the care of the University Hospitals
Bristol NHS foundation Trust have participated in the
development work underpinning this research. They
gave feedback about the initial design of the
intervention and data collection methods.
2. Ten young people (aged 11–17 years) from the
Bristol Young Persons Advisory Group (YPAG) also
participated in the development work underpinning
this research. This group is comprised of young
people who are interested in healthcare and
research who meet regularly in Bristol to help
researchers with their projects. This group reviewed
and gave feedback on the participant facing
documents, data collection methods and details of
the intervention involved with this study.
Discussion
Dietary intakes and physical activity are considered key
components of managing the CVD risk for individuals
with FH. However, there is a recognised lack of research
to support the efficacy of adhering to the current guide-
lines for promoting a favourable CVD risk factor profile.
Furthermore, the best approach to promote behavioural
changes in this population is yet to be determined. This
paper describes the protocol of a pilot, randomised
waitlist-controlled trial designed to estimate the feasibil-
ity and acceptability of conducting a family-based nutri-
tion and physical activity intervention to young people,
and their affected parent, with FH. The data obtained in
this trial could be used to inform the development of a
future clinical trial powered to detect clinically signifi-
cant changes in the chosen outcome measures, if
deemed appropriate.
Study status
The study is now closed for recruitment and data collec-
tion was completed in March 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40814-020-00584-3.
Additional file 1. SPIRIT 2013 statement checklist: recommended items
to address in a clinical trial protocol and related documents.
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